Covariate analysis for CPH modeling of PFS indicated a higher predicted rate of disease progression or death with lower baseline albumin level or higher baseline nivolumab clearance but not with other baseline covariates for patients with advanced RCC. This evidence concerns the gene ALB and renal cell carcinoma.